Nelson Moussazadeh1, Eric Lis2, Evangelia Katsoulakis3, Sweena Kahn4, Marek Svoboda4, Natalie M DiStefano4, Lily McLaughlin4, Mark H Bilsky1, Yoshiya Yamada5, Ilya Laufer6. 1. Division of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Neurological Surgery, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York. 2. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Radiation Oncology, New York Methodist Hospital, Brooklyn, New York. 4. Division of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. 5. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. 6. Division of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Neurological Surgery, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York. Electronic address: lauferi@mskcc.org.
Abstract
PURPOSE: To characterize local tumor control and toxicity risk in very long-term survivors (>5 years) after high-dose spinal image guided, intensity modulated radiation therapy delivered as single-dose stereotactic radiosurgery (SRS). Previously published spinal SRS outcome analyses have included a heterogeneous population of cancer patients, mostly with short survival. This is the first study reporting the long-term tumor control and toxicity profiles after high-dose single-fraction spinal SRS. METHODS AND MATERIALS: The study population included all patients treated from June 2004 to July 2009 with single-fraction spinal SRS (dose 24 Gy) who had survived at least 5 years after treatment. The endpoints examined included disease progression, surgical or radiation retreatment, in-field fracture development, and radiation-associated toxicity, scored using the Radiation Therapy Oncology Group radiation morbidity scoring criteria and the Common Terminology Criteria for Adverse Events, version 4.0. Local control and fracture development were assessed using Kaplan-Meier analysis. RESULTS: Of 278 patients, 31 (11.1%), with 36 segments treated for spinal tumors, survived at least 5 years after treatment and were followed up radiographically and clinically for a median of 6.1 years (maximum 102 months). The histopathologic findings for the 5-year survivors included radiation-resistant metastases in 58%, radiation-sensitive metastases in 22%, and primary bone tumors in 19%. In this selected cohort, 3 treatment failures occurred at a median of 48.6 months, including 2 recurrences in the radiation field and 1 patient with demonstrated progression at the treatment margins. Ten lesions (27.8%) were associated with acute grade 1 cutaneous or gastrointestinal toxicity. Delayed toxicity ≥ 3 months after treatment included 8 cases (22.2%) of mild neuropathy, 2 (5.6%) of gastrointestinal discomfort, 8 (22.2%) of dermatitides, and 3 (8.3%) of myalgias/myositis. Thirteen treated levels (36.1%) in 12 patients demonstrated progressive vertebral body collapse or endplate fractures at a median of 25.7 months (range 11.6-76.0), of which 5 (14%) became symptomatic and subsequently required percutaneous cement augmentation or surgery. CONCLUSIONS: In the longest-term series to date, high-dose single-fraction spinal SRS retained an excellent safety profile among long-term survivors (>5 years).
PURPOSE: To characterize local tumor control and toxicity risk in very long-term survivors (>5 years) after high-dose spinal image guided, intensity modulated radiation therapy delivered as single-dose stereotactic radiosurgery (SRS). Previously published spinal SRS outcome analyses have included a heterogeneous population of cancerpatients, mostly with short survival. This is the first study reporting the long-term tumor control and toxicity profiles after high-dose single-fraction spinal SRS. METHODS AND MATERIALS: The study population included all patients treated from June 2004 to July 2009 with single-fraction spinal SRS (dose 24 Gy) who had survived at least 5 years after treatment. The endpoints examined included disease progression, surgical or radiation retreatment, in-field fracture development, and radiation-associated toxicity, scored using the Radiation Therapy Oncology Group radiation morbidity scoring criteria and the Common Terminology Criteria for Adverse Events, version 4.0. Local control and fracture development were assessed using Kaplan-Meier analysis. RESULTS: Of 278 patients, 31 (11.1%), with 36 segments treated for spinal tumors, survived at least 5 years after treatment and were followed up radiographically and clinically for a median of 6.1 years (maximum 102 months). The histopathologic findings for the 5-year survivors included radiation-resistant metastases in 58%, radiation-sensitive metastases in 22%, and primary bone tumors in 19%. In this selected cohort, 3 treatment failures occurred at a median of 48.6 months, including 2 recurrences in the radiation field and 1 patient with demonstrated progression at the treatment margins. Ten lesions (27.8%) were associated with acute grade 1 cutaneous or gastrointestinal toxicity. Delayed toxicity ≥ 3 months after treatment included 8 cases (22.2%) of mild neuropathy, 2 (5.6%) of gastrointestinal discomfort, 8 (22.2%) of dermatitides, and 3 (8.3%) of myalgias/myositis. Thirteen treated levels (36.1%) in 12 patients demonstrated progressive vertebral body collapse or endplate fractures at a median of 25.7 months (range 11.6-76.0), of which 5 (14%) became symptomatic and subsequently required percutaneous cement augmentation or surgery. CONCLUSIONS: In the longest-term series to date, high-dose single-fraction spinal SRS retained an excellent safety profile among long-term survivors (>5 years).
Authors: Ori Barzilai; Natalie DiStefano; Eric Lis; Yoshiya Yamada; D Michael Lovelock; Andrew N Fontanella; Mark H Bilsky; Ilya Laufer Journal: J Neurosurg Spine Date: 2017-11-03
Authors: Yoshiya Yamada; Evangelia Katsoulakis; Ilya Laufer; Michael Lovelock; Ori Barzilai; Lily A McLaughlin; Zhigang Zhang; Adam M Schmitt; Daniel S Higginson; Eric Lis; Michael J Zelefsky; James Mechalakos; Mark H Bilsky Journal: Neurosurg Focus Date: 2017-01 Impact factor: 4.047
Authors: Anne M Walling; Phillip J Beron; Tania Kaprealian; Patrick A Kupelian; Neil S Wenger; Susan A McCloskey; Christopher R King; Michael Steinberg Journal: J Palliat Med Date: 2017-02-23 Impact factor: 2.947
Authors: Dennis T Lockney; Angela Y Jia; Eric Lis; Natalie A Lockney; Chengbao Liu; Benjamin Hopkins; Daniel S Higginson; Yoshiya Yamada; Ilya Laufer; Mark Bilsky; Adam M Schmitt Journal: J Neurosurg Spine Date: 2018-01-26
Authors: Dennis T Lockney; Benjamin Hopkins; Natalie A Lockney; Christian Z Coleman; Elena Rubin; Eric Lis; Yoshiya Yamada; Adam Schmitt; Daniel Higginson; Mark H Bilsky; Ilya Laufer Journal: Ann Transl Med Date: 2019-05
Authors: Christopher Cao; Daniel Wang; David H Tian; Ashley Wilson-Smith; James Huang; Andreas Rimner Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: William C Newman; John Berry-Candelario; Jemma Villavieja; Anne S Reiner; Mark H Bilsky; Ilya Laufer; Ori Barzilai Journal: Neurosurgery Date: 2021-04-15 Impact factor: 4.654
Authors: Scott L Zuckerman; Ilya Laufer; Arjun Sahgal; Yoshiya J Yamada; Meic H Schmidt; Dean Chou; John H Shin; Naresh Kumar; Daniel M Sciubba Journal: Spine (Phila Pa 1976) Date: 2016-10-15 Impact factor: 3.241